MX2022015609A - ANTICUERPOS ANTI-TGFß Y USOS TERAPÉUTICOS DE ESTOS. - Google Patents

ANTICUERPOS ANTI-TGFß Y USOS TERAPÉUTICOS DE ESTOS.

Info

Publication number
MX2022015609A
MX2022015609A MX2022015609A MX2022015609A MX2022015609A MX 2022015609 A MX2022015609 A MX 2022015609A MX 2022015609 A MX2022015609 A MX 2022015609A MX 2022015609 A MX2022015609 A MX 2022015609A MX 2022015609 A MX2022015609 A MX 2022015609A
Authority
MX
Mexico
Prior art keywords
antibodies
tgfî2
therapeutic uses
antigen binding
binding proteins
Prior art date
Application number
MX2022015609A
Other languages
English (en)
Spanish (es)
Inventor
Sandra Ann Marie Lightle
Lisa Marie Bergeron
Henry Luis Campos
Gary F Bammert
Catherine J Strietzel
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2022015609A publication Critical patent/MX2022015609A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022015609A 2020-06-08 2021-06-08 ANTICUERPOS ANTI-TGFß Y USOS TERAPÉUTICOS DE ESTOS. MX2022015609A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036092P 2020-06-08 2020-06-08
PCT/US2021/036347 WO2021252455A1 (en) 2020-06-08 2021-06-08 ANTI-TGFβ ANTIBODIES AND THERAPEUTIC USES THEREOF

Publications (1)

Publication Number Publication Date
MX2022015609A true MX2022015609A (es) 2023-04-20

Family

ID=76708478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015609A MX2022015609A (es) 2020-06-08 2021-06-08 ANTICUERPOS ANTI-TGFß Y USOS TERAPÉUTICOS DE ESTOS.

Country Status (13)

Country Link
US (1) US20220119513A1 (enExample)
EP (1) EP4161654A1 (enExample)
JP (1) JP7798805B2 (enExample)
KR (1) KR20230022974A (enExample)
CN (1) CN115803342A (enExample)
AU (1) AU2021287868A1 (enExample)
BR (1) BR112022024195A2 (enExample)
CA (1) CA3186707A1 (enExample)
CO (1) CO2023000068A2 (enExample)
DK (1) DK202370008A1 (enExample)
MX (1) MX2022015609A (enExample)
PH (1) PH12022500030A1 (enExample)
WO (1) WO2021252455A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
CA3194936A1 (en) 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
CA3232382A1 (en) * 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof
KR20250137204A (ko) 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
AU2023415535A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
CN117106082B (zh) * 2023-09-15 2024-10-29 成都蓉生药业有限责任公司 一种抗TGFβ的人源化纳米抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
MXPA01009363A (es) 1999-03-18 2002-06-04 Merck Patent Gmbh Proteina para bloquear la adhesion de plaquetas.
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1130098A3 (en) 2000-02-29 2003-09-10 Pfizer Products Inc. Mammalian osteoregulins
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2469833C (en) 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
CA2632799A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
JP6495884B2 (ja) * 2013-03-11 2019-04-03 ジェンザイム・コーポレーション 改変抗ｔｇｆベータ抗体および抗原結合フラグメント
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TW202506185A (zh) * 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
US20200392219A1 (en) * 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
EP3877055A1 (en) * 2018-11-05 2021-09-15 Ludwig Institute for Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof

Also Published As

Publication number Publication date
EP4161654A1 (en) 2023-04-12
DK202370008A1 (en) 2023-01-31
KR20230022974A (ko) 2023-02-16
JP2023530663A (ja) 2023-07-19
AU2021287868A1 (en) 2022-12-22
WO2021252455A1 (en) 2021-12-16
US20220119513A1 (en) 2022-04-21
PH12022500030A1 (en) 2024-02-26
JP7798805B2 (ja) 2026-01-14
CO2023000068A2 (es) 2023-01-16
BR112022024195A2 (pt) 2023-02-07
CA3186707A1 (en) 2021-12-16
CN115803342A (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
PH12022500030A1 (en) Anti-tgf㟠antibodies and therapeutic uses thereof
PH12020500643A1 (en) Anti-ngf antibodies and methods thereof
MX2023004020A (es) Anticuerpos anti-ngf y métodos para su uso.
UA108066C2 (uk) Білки, що зв'язуються з cgrp-рецепторами людини
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
PH12017501402A1 (en) Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
EP4374922A3 (en) Anti-c5 antibodies and uses thereof
MX2019013998A (es) Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
PT2069324E (pt) Amino piridina fundida como inibidor da hsp90
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
GEAP202114964A (en) ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF
MY149630A (en) Antibodies against amyloid-beta peptide
PH12022551462A1 (en) Ilt3-binding agents and methods of use thereof
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
AU2016210835A8 (en) Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
ZA202110285B (en) Antibodies and methods of use
MY149492A (en) Immunoglobulins directed against nogo
PH12022550277A1 (en) Biopharmacuetical compositions and related methods
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
ZA202106627B (en) Treatment of headache using anti-cgrp antibodies